Study title:
Evaluation of the safety of Feline Herpes Virus, bivalent deleted live vaccine, administered as intranasal vaccine to cats
EU record number:
B/BE/04/BV1
Company / Sponsor:
Pfizer, Animal Health Group
Treated organism:
cats
Indication category:
prevention and/or reduction of infection caused by Feline immunodeficiency virus (FIV)
Genetic modification:
gene for the env glycoprotein or gene for the gag protein of the Feline immunodeficiency virus (FIV)
Method of transfer of nucleic acid of interest:
Feline Herpes Virus
Route of administration:
intranasal
Locations in Belgium:
Mechelen, Sint Katelijne-Waver and Schaerbeek
Nr of subjects:
at least 40 animals, maximum 1000 animals
Foreseen duration:
1 year
Type of procedure:
Deliberate release only
Information for the public
-
Public information presented according to the provisions of Directive 2001/18/EC
-
-
-
B/BE/04/BV1 - Summary Notification Information Format (SNIF)Information related to the decision procedure
-
15 July 2005: The Biosafety Advisory Council issues a positive advice (with conditions) for this trial.
-
1 September 2005: The Federal Minister gives a final decision (positive) for this trial, reminding the conditions requested by the Biosafety Advisory Council in its advice.